Home/Filings/4/0001437749-25-021051
4//SEC Filing

Foster Jonathan P. 4

Accession 0001437749-25-021051

CIK 0001659617other

Filed

Jun 22, 8:00 PM ET

Accepted

Jun 23, 4:35 PM ET

Size

17.0 KB

Accession

0001437749-25-021051

Insider Transaction Report

Form 4
Period: 2025-06-20
Transactions
  • Exercise/Conversion

    Common Stock

    2025-06-20+2,71114,704 total
  • Exercise/Conversion

    Common Stock

    2025-06-22+4,32818,371 total
  • Purchase

    Common Stock

    2025-06-23$0.37/sh+270,270$100,000287,587 total
  • Exercise/Conversion

    Restricted Stock Units

    2025-06-202,711231,838 total
    Common Stock (2,711 underlying)
  • Purchase

    Series E Warrants

    2025-06-23810,8101,038,320 total
    Exercise: $0.37Common Stock (810,810 underlying)
  • Tax Payment

    Common Stock

    2025-06-20$0.27/sh661$17614,043 total
  • Tax Payment

    Common Stock

    2025-06-22$0.27/sh1,054$28117,317 total
  • Exercise/Conversion

    Restricted Stock Units

    2025-06-224,328227,510 total
    Common Stock (4,328 underlying)
Footnotes (5)
  • [F1]Restricted stock units convert into common stock on a one-for-one basis.
  • [F2]Shares withheld for payment of taxes upon vesting of restricted stock unit awards.
  • [F3]On June 20, 2022, the reporting person was granted 10,846 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.
  • [F4]On June 22, 2023, the reporting person was granted 17,313 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.
  • [F5]On June 23, 2025, the reporting person acquired 270,270 shares of common stock and Series E warrants to purchase 810,810 shares of common stock at a purchase price of $0.37 per share and accompanying warrants in a public offering. The Series E warrants will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the Series E warrants and will expire five years from the date of such approval.

Issuer

Moleculin Biotech, Inc.

CIK 0001659617

Entity typeother

Related Parties

1
  • filerCIK 0001545414

Filing Metadata

Form type
4
Filed
Jun 22, 8:00 PM ET
Accepted
Jun 23, 4:35 PM ET
Size
17.0 KB